Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Similar articles for PubMed (Select 20121419)

1.

Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

Schouten JT, Krambrink A, Ribaudo HJ, Kmack A, Webb N, Shikuma C, Kuritzkes DR, Gulick RM.

Clin Infect Dis. 2010 Mar 1;50(5):787-91. doi: 10.1086/650539.

2.

Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.

Bock P, Fatti G, Grimwood A.

Int Health. 2013 Jun;5(2):132-8. doi: 10.1093/inthealth/iht002.

PMID:
24030113
3.

Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.

Pillay P, Ford N, Shubber Z, Ferrand RA.

PLoS One. 2013 Jul 22;8(7):e68995. doi: 10.1371/journal.pone.0068995. Print 2013. Review.

4.

[Changes in driving skills in patients who start treatment with efavirenz].

Poquet I, Bourguet M, Cioaia S, Tornero C.

Enferm Infecc Microbiol Clin. 2014 Jan;32(1):59-60. doi: 10.1016/j.eimc.2013.05.008. Epub 2013 Jul 17. Spanish. No abstract available.

PMID:
23871096
5.

Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.

Takuva S, Evans D, Zuma K, Okello V, Louwagie G.

Pan Afr Med J. 2013 May 3;15:5. doi: 10.11604/pamj.2013.15.5.1889. Print 2013.

6.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;6:CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
7.

Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.

Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, Ciaffi L, Sobry A, Bastos R, Nunes E, Rouzioux C, Jani I, Calmy A; CARINEMO study group.

Lancet Infect Dis. 2013 Apr;13(4):303-12. doi: 10.1016/S1473-3099(13)70007-0. Epub 2013 Feb 20.

PMID:
23433590
8.

Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.

Shubber Z, Calmy A, Andrieux-Meyer I, Vitoria M, Renaud-Théry F, Shaffer N, Hargreaves S, Mills EJ, Ford N.

AIDS. 2013 Jun 1;27(9):1403-12. doi: 10.1097/QAD.0b013e32835f1db0. Review.

PMID:
23343913
9.

Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.

Dailly E, Allavena C, Bouquié R, Deslandes G, Raffi F, Jolliet P.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):42-6. doi: 10.1089/AID.2012.0188. Epub 2012 Dec 16.

PMID:
23148588
10.

Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique.

Chu KM, Manzi M, Zuniga I, Biot M, Ford NP, Rasschaert F, Zachariah R.

Int J STD AIDS. 2012 Jun;23(6):403-7. doi: 10.1258/ijsa.2009.009328.

PMID:
22807533
11.

NNRTIs: future prospects.

Dellamonica P, Di Perri G, Garraffo R.

Med Mal Infect. 2012 Jul;42(7):296-300. doi: 10.1016/j.medmal.2012.05.005. Epub 2012 Jun 23. Review.

PMID:
22727648
12.

No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.

Van Welzen B, Mudrikova T, Arends J, Hoepelman A.

HIV Med. 2012 Aug;13(7):448-52. doi: 10.1111/j.1468-1293.2012.00995.x. Epub 2012 Mar 14.

PMID:
22413955
13.

Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings: evidence, clinical practice and modelling projections.

Uthman O, Mofenson LM, Nachega JB.

AIDS. 2012 Mar 13;26(5):639-41. doi: 10.1097/QAD.0b013e3283509a40. No abstract available.

PMID:
22398571
14.

Hyperhidrosis related to nevirapine therapy.

Belda A, Borrás-Blasco J, Rosique-Robles D, Jiménez I, López-Montes L, Casterá E.

Int J STD AIDS. 2012 Jan;23(1):61-3. doi: 10.1258/ijsa.2009.009080.

PMID:
22362694
15.

Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.

Li ZC, Li HJ, Dai LL, Gao YQ, Cai WP, Li HY, Huang XJ, Zhang T, Wu H.

Chin Med J (Engl). 2010 Dec;123(24):3587-90.

PMID:
22166636
16.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

17.

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.

Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, Merino D, de Los Santos-Gil I, Macías J, González-Serrano M, Camacho A, Parra-García G, Pineda JA; SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

J Antimicrob Chemother. 2011 Nov;66(11):2605-14. doi: 10.1093/jac/dkr357. Epub 2011 Sep 7.

18.

Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.

Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R.

Clin Infect Dis. 2011 Oct;53(7):716-24. doi: 10.1093/cid/cir447.

19.

Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.

Shah I, Swaminathan S, Ramachandran G, Kumar AK, Goray A, Chaddha U, Tayal S, Lala M.

Indian Pediatr. 2011 Dec;48(12):943-7. Epub 2011 Mar 15.

20.

Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens.

Maggi P, Bellacosa C, Carito V, Perilli F, Lillo A, Volpe A, Trillo G, Angiletta D, Regina G, Angarano G.

J Antimicrob Chemother. 2011 Apr;66(4):896-900. doi: 10.1093/jac/dkq507. Epub 2011 Jan 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk